drugset
drugset / Trial / NCT01079325

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325 ↗

Phase 2 Completed 170 enrolled Sangamo Therapeutics Juvenile Diabetes Research Foundation · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to evaluate the clinical effects of the investigational drug, SB-509, in subjects with diabetic neuropathy.

Timeline

Start
2009-11
Primary completion
2015-05
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-509 Unknown 60 mg Other

Indications

diabetic polyneuropathy type 1 diabetes mellitus type 2 diabetes mellitus